by David Wallace New Treatment Targets Root Cause of ET: INCA033989 Trial Shows Powerful Results June 15, 2025 – EHA Congress, Milan Incyte has announced positive, late-breaking data from the first clinical studies of its experimental therapy INCA033989—an antibody designed to precisely target a genetic driver of disease in patients with Essential Thrombocythemia (ET). The […]
Phase 3 Clinical Trial for Polycythemia Vera
Unfortunately for some polycythemia vera (PV) patients, current treatment options may not be fully effective or well-tolerated and may cause serious side effects. But a promising investigational treatment is currently being clinically evaluated. Rusfertide, also known as PTG-300, is an investigational new drug designed to slow the release of iron into the bone marrow. The […]
Is there a Connection between MPNs and Autoimmune Diseases?
by David Wallace Patients are Asking – Episode 2 of 3 In this interview with MPN expert, Dr. Angela Fleischman, we discuss the latest treatments for myelofibrosis (MF) and when a clinical trial should be considered. Research has linked MPNs to a pre-disposition to autoimmune disorders such as Lupus, Crohn’s disease and Psoriasis just to […]
Momelotinib: emerging treatment for myelofibrosis patients with anemia
Abstract The suite of marked anemia benefits that momelotinib has consistently conferred on myelofibrosis (MF) patients stem from its unique inhibitory activity on the BMP6/ACVR1/SMAD and IL-6/JAK/STAT3 pathways, resulting in decreased hepcidin (master iron regulator) expression, higher serum iron and hemoglobin levels, and restored erythropoiesis. Clinical data on momelotinib from the phase 2 and the […]
MPN Clinical Trials 2021 Update
Patients are Asking – MPN Expert Dr. Andrew Kuykendall Episode 2 of 3 Update on MPN Clinical Trials in 2021. The PDUFA date is the end of the review period, where the FDA has to make a decision or respond to a New Drug Application (NDA) or a Biologics License Application (BLA). Ropeginterferon and Pacritinib […]